
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCAD CRISPR/Cas9 KO Plasmid (m) | sc-418938 | 20 µg | $397.00 |
Acadm encodes medium-chain acyl-CoA dehydrogenase (MCAD), a mitochondrial flavoprotein that catalyzes the first dehydrogenation step in β-oxidation of medium-chain fatty acids, linking lipid catabolism to cellular ATP production and redox balance. MCAD activity supports metabolic flexibility during fasting and high-energy demand by fueling the TCA cycle and oxidative phosphorylation through acetyl-CoA and electron transfer via ETF/ETFDH. Disruption of Acadm perturbs mitochondrial fatty acid oxidation, alters acylcarnitine profiles, and can promote secondary effects on oxidative stress responses and lipid signaling networks. MCAD deficiency is a well-established inborn error of metabolism associated with impaired fatty acid utilization, making Acadm a relevant node for studying mitochondrial metabolic homeostasis in mouse models.
MCAD CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Acadm gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Acadm together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Acadm open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MCAD protein expression.
This CRISPR knockout system enables efficient generation of Acadm-deficient cell models for investigation of MCAD signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.